All News
Best of 2018: Patients May Not Fill Your Prescription
A new study linking administrative claims and electronic health records (EHRs) shows that nearly 40% of patients fill and take newly prescribed methotrexate (MTX), tofacitinib or biologics.
Kan et al set out to estimate the extent and predictors of primary nonadherence in rheumatoid arthritis (RA) patients who received new prescriptions for methotrexate, biologics or tofacitinib.
Read ArticleBest of 2018: Ustekinumab May be Effective in Lupus
Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory param
Read ArticleBest of 2018: Unproven But Profitable Stem Cell Clinics
Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.
Read ArticleMourning the Loss of NIAMS Director Stephen Katz, MD, PhD
The following tribute to the late Dr. Steven Katz appeared on the NIH website.
Read ArticleRheumNow Podcast – Rheumatologist Salaries (12.21.18)
Dr. Jack Cush reviews the news from RheumNow for the week ending 12/21/18.
Read ArticleZolendronate Protects Against Fracture in Osteopenia
The NEJM reports that the use of zoledronate significantly reduces the risk of nonvertebral or vertebral fragility fractures in women with osteopenia.
Read ArticleReassuring VTE Data for Tofacitinib
No significant differences in risk for venous thromboembolism (VTE) were seen in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) and those receiving tumor necrosis factor (TNF) inhibitors, analysis of administrative data showed.
Read ArticleNailfold Videocapillaroscopy in Dermatomyositis
A study of nailfold videocapillaroscopy (NVC) in patients with idiopathic inflammatory myopathies (IIMs) finds abnormalities in more than half of patients suggesting this could be a useful clinical tool in diagnosing and managing patients with IIM.
Read ArticleRheumatologist and Physician Salaries for 2018
Medpage Today has published the results of their 2018 Rheumatology Specialty Salaray Survey.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
David McGinnis demcginnis ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)